The Korea Disease Control and Prevention Agency (KDCA) dismissed concerns about potential supply disruptions for the high‑risk group influenza National Immunization Program (NIP). Initial delivery delays from Sanofi were managed by adjusting procurement quantities. The agency confirmed that the 12.33 million doses required for the 2026‑2027 seasonal national immunization will be supplied according to the vaccination schedule.
KDCA stated that the government has secured the necessary vaccine volume and expects no interruption in delivery. The upcoming seasonal NIP targets individuals aged 65 and over, children from six months to 13 years, and pregnant women.
The agency’s response addresses recent media reports suggesting possible shortages, reaffirming confidence in the planned supply chain.
Análisis de mercado17 sept 2026•3 min de lectura
KDCA assures timely supply of 12.33 million influenza NIP doses despite Sanofi delay
The Korea Disease Control and Prevention Agency says the 12.33 million influenza vaccine doses for the 2026‑2027 national immunization program will be delivered on schedule, despite early supply delays from Sanofi.
Recopilado por el equipo de Pharmacountry · Fuente: KPA News
Temas:
Calificaciones
(0)
(0)
(0)
(0)
(0)
Deja tu valoración